In a new job - March 28, 2018
New Chief Scientific Officer at Oncopeptides
Oncopeptides has broaden its management team with the appointment of Dr Christian Jacques as Executive Vice President Clinical Strategy and Chief Scientific Officer (CSO). Jacques has more than 25 years of experience in clinical development of new chemical entity’s within hematology-oncology leading to approval of several innovative pharmaceuticals in oncology and hematology, including pomalidomide. “The […]
In a new job - March 15, 2018
Dignitana appoints three new board members
Dignitana announces the appointment of Anette Cronström, Thomas Joyce and Thomas Kelly to the Board of Directors for Dignitana, Inc., which governs operations in the U.S. Also announced is the promotion of James McKinney who will now serve as President and Chief Operating Officer of Dignitana, Inc.. McKinney has been the company’s Chief Operating Officer […]
In a new job - March 15, 2018
Modus Therapeutics appoints new CMO
The company has appointed Dr. John Öhd as the Company’s Chief Medical Officer (CMO). Öhd joins Modus from Medivir, where he was CMO and a member of the company’s Executive Management team. Before taking up his current position, John was Medivir’s Director of Clinical R&D. Prior to joining Medivir, John was senior director of Experimental Medicine at Shire […]
In a new job - February 27, 2018
New Director at FIMM
The University of Helsinki has recruited Professor Mark Daly of the Broad Institute of MIT and Harvard and Massachusetts General Hospital to lead the Institute for Molecular Medicine Finland (FIMM). Daly succeeds Academy Professor Jaakko Kaprio, and has been appointed with effect from February 1, 2018. While spending most of his time in Finland, Daly will continue […]
In a new job - February 21, 2018
New General Manager Nordics at Bristol Myers Squibb
Iddo Leshem commenced his role as General Manager, Bristol Myers Squibb (BMS) Nordics in January 2018. The Nordics’ business has over 200 employees and Iddo will be based at BMS’s Swedish office in Solna, Stockholm. “Our mission is to translate cutting edge science into innovative medicines that extend and improve lives of patients combating serious […]
In a new job - February 9, 2018
Symcel expands
The company is expanding to bring its technology to the clinical antimicrobial susceptibility testing (AST) markets. The company is currently commercially leveraging the Horizon 2020 funded Phase II (AST) project – in which multi-resistant bacterial infections will be clinically validated using Symcel’s screening method. “Our business development strategy has evolved and is now twofold: we […]
